GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (OTCPK:CHMMF) » Definitions » Total Long-Term Assets

CHMMF (Chimeric Therapeutics) Total Long-Term Assets : $7.30 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Chimeric Therapeutics's Total Long-Term Assets for the quarter that ended in Dec. 2024 was $7.30 Mil.


Chimeric Therapeutics Total Long-Term Assets Historical Data

The historical data trend for Chimeric Therapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Total Long-Term Assets Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Total Long-Term Assets
10.58 9.63 8.74 8.00

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Total Long-Term Assets Get a 7-Day Free Trial 9.12 8.74 8.39 8.00 7.30

Chimeric Therapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.


Chimeric Therapeutics Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimeric Therapeutics Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics Headlines

From GuruFocus

Chimeric Therapeutics Ltd FNN Investor Event Transcript

By GuruFocus Research 02-13-2024

Chimeric Therapeutics Ltd Investor Webinar Transcript

By GuruFocus Research 02-13-2024